Record · readability.com
What US Healthcare Professionals Should Know About Tacabrutideg and the Evolving Landscape of B-Cell Malignancy Care
readability.com · 26 September 2026 · 5 min read
A post on readability.com, published 26 September 2026, has not been cited by any blog yet (corpus.blog, measured 13 October 2026).
A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Words blogs link it with | 0 |
|---|---|
| External links | 1 |
| Length | 1,077 |
Cited by
No blog we hold has cited this post yet.
Links from this post
Link
Host
beonemedaffairs.com
Elsewhere on readability.com (1)
readability.com
Similar posts
Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Q&A October is ECTRIMS Month
multiple-sclerosis-research.org
1 Oct 2026
A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Too much CD20 not enough BTKi
multiple-sclerosis-research.org
10 Sept 2026
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Don’t get BiTEn by bispecific T-cell engagers
first10em.com
9 Mar 2026
A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Back Button
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with <em>KRAS G12D</em> mutations.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs
30 Sept 2026
Something wrong here? Report a problem